The profile of ErbB-Her family genes copy number assessed by real-time PCR in parathyroid adenoma and hyperplasia associated with sporadic primary hyperparathyroidism

• Autorzy: Bednarz N. , Blaut K. , Sworczak K. , Oseka T. , Bielawski K.P.
• Języki publikacji: EN

Abstrakty

EN

 Hyperparathyroidism (pHPT) is a relatively frequent endocrinopathy, however, the molecular mechanisms of its etiology remain poorly understood. This disorder is mainly associated with benign tumours (adenoma) and hyperplasia of the parathyroid, hence, the focus is directed also to genes that are likely to be involved in carcinogenesis. Among such genes are ErbB/Her family genes already used in diagnosis of other tumours (e.g., breast carcinoma) and reported also to play a role in development of endocrine lesions. So far, ErbB-1/Her-1/EGFR expression has been detected in pHPT-associated adenomas and hyperplasia as opposed to no expression in normal parathyroid tissue. Moreover, losses or gains of the fragments of chromosomes where ErbB/Her genes are located have been reported. In this study, the gene dosage of ErbB/Her family genes were determined for the first time in parathyroid adenomas, hyperplasia and morphologically unchanged tissue in order to establish their putative role in the development of the disease. Genomic DNA was isolated from 33 patients with sporadic hyperparathyroidism and the gene copy numbers were assessed using real-time PCR. The ErbB/Her genes' profile was unaltered in most of the examined samples. Two low-level amplifications of ErbB-1/Her-1/EGFR gene, two deletions of ErbB-2/Her-2, and six deletions of ErbB-4/Her-4 were found. The ErbB-3/Her-3 gene remained unaffected. No correlation with clinical parameters was found for any gene. Both the low number of alterations and a lack of their associations with clinical parameters exclude the prognostic value of the ErbB/Her genes family in parathyroid tumourigenesis. Nevertheless, the ErbB-4/Her-4 deletions seem to be interesting for further investigations, especially in the context of PTH secretion.

Słowa kluczowe

EN

parathyroid hyperplasia; parathyroid adenoma; hyperparathyroidism; parathyroid hormone; parathyroid tumourigenesis; ErbB-Her family gene profile; sporadic primary hyperparathyroidism; real-time polymerase chain reaction

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2009
• Tom: 56
• Numer: 1
• Opis fizyczny: p.83-88,fig.,ref.

Twórcy

autor

Bednarz N.

• University of Gdansk and Medical University of Gdansk, Kladki 24, 80-822 Gdansk, Poland

autor

Blaut K.

autor

Sworczak K.

autor

Oseka T.

autor

Bielawski K.P.

Bibliografia

• Adami S, Marcocci C, Gatti D (2002) Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 17 (Suppl 2): N18-N23.
• Agarwal SK, Schröck E, Kester MB, Burns AL, Heffess CS, Marx SJ (1998) Comparative genomic hybridization analysis of human parathyroid tumours. Cancer Genet Cytogenet 106: 30-36.
• Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K (2005) Gene amplification and protein expression of EGFR and HER-2 by chromogenic in situ hybridization and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 58: 1076-1080.
• Brandt B, Vogt U, Harms F, Bosse U, Zänker KS, Assmann G (1995) Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene 159: 29-34.
• Carling T (2001) Molecular pathology of parathyroid tumours. Trends Endocrinol Metab 12: 53-58.
• Cozzolino M, Lu Y, Sato T, Yang J, Gonzalez Suarez I, Branaccio D, Slatopolsky E, Dusso AS (2005) A critical role for enhanced TGF-α and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 289: F1096-F1102.
• Dimova I, Zaheriev B, Raitcheva S, Dimitrov R, Doganova N, Tonacheva D (2006) Tissue microarray analysis of EGFR and ErbB-2 copy number changes in ovarian tumours. Int J Gynecol Cancer 16: 145-151.
• Forsberg L, Björk E, Hashemi J, Zdenius J, Höög A, Farnebo L-O, Reimers M, Larsson C (2005) Distinction in gene expression profiles demonstrated in parathyroid adenomas by high density oligoarray technology. Eur J Endocrinol 152: 459-470.
• Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, Schmid KW, Bockisch A, Otterbach F (2005) Prognostic value of c-erbB.2 expression in papillary thyroid carcinoma. Nuklearmedizin 44: 179-182.
• Garcia JL, Tardio JC, Gutierrez NC, Gonzales MB, Polo JR, Hernandez JM, Menarguez J (2002) Chromosomal imbalances identified by comperative genomic hybridization in sporadic parathyroid adenomas. Eur J Endocrinol 146: 209-213.
• Gülkesen KH, Kilicarslan B, Altunbas HA, Karpuzoglu G (2001) EGFR and p53 expression and proliferative activity in parathyroid adenomas; an immunohistochemical study. APMIS 109: 870-874.
• Hemmer S, Wasenius VM, Haglund C, Zhu Y, Knuutila S, Franssila K, Joensuu H (2001) Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol 158: 1355-1362.
• Imanishi Y (2002) Molecular pathogenesis of tumourigenesis in sporadic parathyroid adenomas. J Bone Miner Metab 20: 190-195.
• Kameyama K, Takami H, Sanders D, Giordano TJ (2000) Surgical pathology of hyperparathyroidism. Biomed Pharmacother 54 Suppl 1: 42-45.
• Kytölä S, Farnebo F, Obara T, Isola J, Grimelius L, Farnebo L-O, Sandelin K, Larsson C (2000) Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 157: 579-586.
• Lee DH, Lee GK, Kong SY, Kook MC, Yang SK, Park SY, Park SH, Keam B, Park do J, Cho BY, Kim SW, Chung KW, Lee ES, Kim SW (2007) Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 60: 881-884.
• Marx SJ (2000) Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 343: 1863-1874.
• Miedlich S, Krohn K, Paschke R (2003) Update on genetic and clinical aspects of primary hyperparathyroidism. Clin Endocrinol (Oxf) 59: 539-554.
• Monson JP (2000) The epidemiology of endocrine tumours. Endocr Relat Cancer 7: 29-36.
• Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RSK, Arnold A (1998) Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 83: 1766-1770.
• Sadler GP, Morgan JM, Jasani B, Douglas-Jones A, Wheeler MH (1996) Epidermal growth factor receptor status in hyperparathyroidism immunohistochemical and in situ hybridization study. World J Surg 20: 736-743.
• Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G (2008) Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 10: R2.
• Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, Smith RC (2005) Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochiemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29: 1125-1134.
• Schwartz S, Caceres C, Morote J, de Torres I, Rodriguez-Vallejo JM, Gonzalez J, Reventos J (1998) Over-expression of epidermal growth factor receptor and c-erbB-2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. Int J Cancer 76: 464-467.
• Sworczak K, Zaczek A, Babinska A, Lisowska U, Bielawski KP, Falkiewicz B (2002) Gene copy numbers of erbB oncogenes in human pheochromocytoma. Oncol Rep 9: 1373-1378.
• Vogt U, Bielawski K, Schlotter CM, Bosse U, Falkiewicz B, Podhajska AJ (1998) Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 223: 375-380.
• Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H (2002) Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15: 116-124.
• Younes NA, Shafagoj Y, Khatib F, Ababneh M (2005) Laboratory screening for hyperparathyroidism. Clin Chim Acta 353: 1-12.
• Zaczek A, Brandt B, Bielawski KP (2005) The diverse signaling network of EGFR, HER-2, HER-3 and HER-4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 20: 1005-1015.
• Zaczek A, Welnicka-Jaskiewicz M, Bielawski KP, Jaskiewicz J, Badzio A, Olszewski W, Rhone P, Jassem J (2008) Gene copy numbers of HER family in breast cancer. J Cancer Res Clin Oncol 134: 271-279.